Compare HNVR & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | AARD |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 165.8M |
| IPO Year | 2022 | 2025 |
| Metric | HNVR | AARD |
|---|---|---|
| Price | $26.98 | $6.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $24.50 | $15.29 |
| AVG Volume (30 Days) | 55.3K | ★ 113.1K |
| Earning Date | 04-27-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ 43.11 |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.49 | N/A |
| Revenue Next Year | $8.61 | N/A |
| P/E Ratio | $34.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $3.35 |
| 52 Week High | $27.83 | $17.94 |
| Indicator | HNVR | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 57.46 | 51.11 |
| Support Level | $22.09 | $4.99 |
| Resistance Level | N/A | $8.02 |
| Average True Range (ATR) | 0.70 | 0.77 |
| MACD | -0.06 | -0.14 |
| Stochastic Oscillator | 40.29 | 39.31 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.